GLAND vs SANOFICONR: Stock Comparison
GLAND PHARMA is the larger company by market capitalisation. SANOFI CONS HEALTHC IND L shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLAND leads 4; SANOFICONR leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLAND | SANOFICONR |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLAND | SANOFICONR |
|---|---|---|
| Live Price | ₹3,092 | ₹3,371.6 |
| Day Change | 0.57% | -2.78% |
| Volume | 61,400 | 14,854 |
| 52-Week High | ₹3,171 | ₹5,255 |
| 52-Week Low | ₹1,573.6 | ₹3,168.2 |
| Distance from 52W High | -2.49% | -35.84% |
Valuation
| Metric | GLAND | SANOFICONR |
|---|---|---|
| Market Cap | ₹51,056 Cr | ₹7,795 Cr |
| P/E Ratio | 44.78x | 28.64x |
| P/B Ratio | 4.88x | 23.02x |
| EPS | ₹68.47 | ₹29.87 |
| Book Value | ₹628.68 | ₹166.73 |
| Dividend Yield | 0.66% | 2.16% |
Growth
| Metric | GLAND | SANOFICONR |
|---|---|---|
| Revenue Growth (TTM YoY) | 22.3% | 32.8% |
| EPS Growth (TTM YoY) | 96.4% | 35.7% |
| Qtr Sales Growth | 0% | 2.84% |
| Qtr Profit Growth | 0% | 1.47% |
Profitability & Leverage
| Metric | GLAND | SANOFICONR |
|---|---|---|
| ROE | 12.02% | 67.16% |
| ROCE | 17.2% | 2,813.76% |
| Net Margin | 16.18% | 27.58% |
| Operating Margin | 38.8% | 37.04% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | GLAND | SANOFICONR |
|---|---|---|
| Promoter Holding | 45.75% | 71.27% |
| FII Holding | 10.36%▲ 1.62 pp | 2.48%▼ 0.12 pp |
| DII Holding | 33.21%▲ 2.77 pp | 18.03%▲ 0.17 pp |
| Public Holding | 10.66%▲ 1.61 pp | 8.22%▼ 0.05 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLAND PHARMA and SANOFI CONS HEALTHC IND L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.